We are live on
!
Find out more
BSAM
Blue Square Asset Management Portfolio holdings
AUM
$247M
1-Year Est. Return
28.81%
This Fund
S&P 500
This Quarter
Est. Return
+7.21%
1 Year Est. Return
+28.81%
3 Year Est. Return
+104.45%
5 Year Est. Return
+91.54%
10 Year Est. Return
–
AUM
$161M
AUM Growth
+$1.15M
(+0.72%)
Cap. Flow
-$8.23M
Cap. Flow
% of AUM
-5.11%
Top 10 Holdings %
Top 10 Hldgs %
50.84%
Holding
94
New
13
Increased
36
Reduced
24
Closed
11
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Adobe
ADBE
|
+$1.32M |
| 2 |
ASML
ASML
|
+$999K |
| 3 |
Carvana
CVNA
|
+$926K |
| 4 |
Enphase Energy
ENPH
|
+$753K |
| 5 |
iShares Core International Aggregate Bond Fund
IAGG
|
+$752K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
iShares Core MSCI Emerging Markets ETF
IEMG
|
+$4.36M |
| 2 |
Norwegian Cruise Line
NCLH
|
+$1.84M |
| 3 |
Palantir
PLTR
|
+$1.5M |
| 4 |
SPDR Gold Trust
GLD
|
+$1.06M |
| 5 |
DraftKings
DKNG
|
+$1.01M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 15.29% |
| 2 | Consumer Discretionary | 10.33% |
| 3 | Financials | 6.96% |
| 4 | Communication Services | 6.81% |
| 5 | Healthcare | 5.76% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
76
Merck
MRK
$322B
| $217K | 0.13% |
2,832
| – | – |
|
77
Visa
V
$684B
| $215K | 0.13% |
993
| – | – |
|
78
Teradyne
TER
$57.6B
| $210K | 0.13% |
+1,287
| New | +$181K |
|
79
Berkshire Hathaway Class B
BRK.B
$1.1T
| $208K | 0.13% |
+697
| New | +$200K |
|
80
American Express
AXP
$227B
| $203K | 0.13% |
1,240
| – | – |
|
81
Eli Lilly
LLY
$1.02T
| $203K | 0.13% |
+735
| New | +$186K |
|
82
Teledyne Technologies
TDY
$30.4B
| $203K | 0.13% |
+464
| New | +$202K |
|
|
CMAX
83
DELISTED
CareMax, Inc. Class A Common Stock
CMAX
| $95K | 0.06% |
412
+78
| +23% | +$18.6K |
|
84
BHP
BHP
$215B
| – | – |
-12,620
| Closed | -$603K |
|
85
State Street SPDR Bloomberg 1-3 Month T-Bill ETF
BIL
$47.1B
| – | – |
-2,904
| Closed | -$266K |
|
86
Biogen
BIIB
$30B
| – | – |
-3,044
| Closed | -$861K |
|
87
CRISPR Therapeutics
CRSP
$4.73B
| – | – |
-7,412
| Closed | -$830K |
|
|
88
DraftKings
DKNG
$11.6B
| – | – |
-21,083
| Closed | -$1.01M |
|
|
89
SPDR Gold Trust
GLD
$131B
| – | – |
-6,445
| Closed | -$1.06M |
|
|
90
Norwegian Cruise Line
NCLH
$8.51B
| – | – |
-68,887
| Closed | -$1.84M |
|
91
Philips
PHG
$25.7B
| – | – |
-26,950
| Closed | -$989K |
|
|
92
Palantir
PLTR
$295B
| – | – |
-62,186
| Closed | -$1.5M |
|
93
PayPal
PYPL
$48.9B
| – | – |
-1,412
| Closed | -$367K |
|
94
Yum China
YUMC
$16.5B
| – | – |
-12,332
| Closed | -$717K |
|
Similar funds
ZEP
BFM
PWS
AB
FPW
CIA
DB
HA
Blue Square Asset Management's Q4 2021 Portfolio in Review
As of Q4 2021, Blue Square Asset Management held 94 positions worth $161M, up 0.72% from $160M the previous quarter. Its ten largest holdings account for 51% of the portfolio.
Blue Square Asset Management withdrew a net $8.23M in Q4 2021, closing 11 positions and reducing 24 holdings. Its most notable exit was Norwegian Cruise Line, an estimated $1.84M position sold in full.
By sector, the portfolio is most concentrated in Technology at 15% of assets, up from 13% a quarter earlier, followed by Consumer Discretionary and Financials.
Against the trend, Blue Square Asset Management opened a new position in Adobe worth $1.2M.
- Blue Square Asset Management's largest Q4 2021 buy was Adobe: 2,118 shares worth $1.2M.
- Blue Square Asset Management added most to Carvana in Q4 2021, an estimated $926K increase.
- Blue Square Asset Management's biggest Q4 2021 reduction was iShares Core MSCI Emerging Markets ETF, cutting an estimated $4.36M.
- Blue Square Asset Management fully exited Norwegian Cruise Line in Q4 2021, selling an estimated $1.84M.
- Blue Square Asset Management's ten largest holdings make up 51% of its $161M portfolio in Q4 2021.
- Blue Square Asset Management opened 13 new positions and closed 11 in Q4 2021.
- Blue Square Asset Management's portfolio value rose 0.72% quarter-over-quarter to $161M.
Based on Blue Square Asset Management's 13F filing for Q4 2021, filed 9 Feb 2022.